The Clinical Effects of Laser Acupuncture on Hospitalized Patients With Severe COVID-19: A Randomized Clinical Trial

被引:0
|
作者
Shojaeddin, Arista [1 ]
Fatemi, Alireza [2 ]
Razzaghi, Zahra [1 ]
Pishgahi, Mehdi [3 ]
Sherafat, Somayeh Jahani [1 ]
Razzaghi, Mohammadreza [1 ]
Shahrzad, Mohamad Karim [4 ]
Anaraki, Nafiseh [4 ]
Salehi, Chiman [4 ]
Amiri, Aslan [4 ]
机构
[1] Shahid Beheshti Univ Med Sci, Laser Applicat Med Sci Res Ctr, Tehran, Iran
[2] Shahid Beheshti Univ Med Sci, Infect Dis & Trop Med Res Ctr, Tehran, Iran
[3] Shahid Beheshti Univ Med Sci, Shohada Tajrish Hosp, Cardiol Dept, Tehran, Iran
[4] Shahid Beheshti Univ Med Sci, Shohada Tajrish Hosp, Internal Med & Endocrinol Dept, Tehran, Iran
关键词
Laser acupuncture; Laser therapy; COVID-19; Severity; THERAPY LLLT; PAIN; IRRADIATION; IL-1-BETA; RELEVANCE; ASTHMA; BLIND; LUNG; ACTS;
D O I
10.34172/jlms.2023.14
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Introduction: The coronavirus disease (COVID-19) was extended to the entire population in China and around the world, and its mortality rate was about 3.4%. The impact of laser therapy on chronic respiratory diseases has been shown in previous studies. This study was aimed at examining the effects of laser acupuncture (LA) on patients with severe COVID-19. Methods: In the present study, 60 patients with a positive reverse transcription-polymerase chain reaction (RT-PCR) test were assigned to the intervention and control groups (30 patients in each group). The intervention group was treated with LA, that is, laser light with low energy on acupuncture points, once a day for five consecutive days. Results: The participants' mean age in the intervention and control groups was 48.96 +/- 12.65 and 53.16 +/- 12.28 respectively; 70% of the patients were male and 30% of them were female. IL6 had a significant reduction in the intervention group (P value = 0.038) in comparison with the control group (P value = 0.535). Furthermore, the mean admission time in the control group was significantly higher than that in the intervention group (P value = 0.047). However, the mortality rate in the intervention group was zero, but three patients in the control group died. Conclusion: Our study showed that LA can be used as supportive therapy for routine treatment in patients with severe COVID-19. Moreover, due to LA safety and it's low cost, it could be recommended as an adjuvant to conventional therapy in patients interested in treating their disease with such a method.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial
    Duarte, M.
    Pelorosso, F.
    Nicolosi, L. N.
    Salgado, V.
    Vetulli, H. M.
    Arquieri, A.
    Azzato, F.
    Coyle, J.
    Davolos, I.
    Fernandez Criado, I.
    Gregori, R.
    Rubio, M. C.
    Sarquis, S. M.
    Whalmann, F.
    Rothlin, R. P.
    EUROPEAN HEART JOURNAL, 2021, 42 : 2965 - 2965
  • [42] Effect of Ammonium Chloride in addition to standard of care in outpatients and hospitalized COVID-19 patients: A randomized clinical trial
    Siami, Zeinab
    Aghajanian, Sepehr
    Mansouri, Somayeh
    Mokhames, Zakiye
    Pakzad, Reza
    Kabir, Kourosh
    Norouzi, Mehdi
    Soleimani, Alireza
    Yaghoobi, Mojtaba Hedayat
    Shadabi, Shahrzad
    Tajbakhsh, Ramin
    Kheirabad, Ali Kargar
    Mozhgani, Sayed-Hamidreza
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2021, 108 : 306 - 308
  • [43] Evaluation of the Efficacy of Arbidol in Comparison with the Standard Treatment Regimen of Hospitalized Patients with Covid-19: A Randomized Clinical Trial
    Yadegarinia, Davood
    Tehrani, Shabnam
    Abolghasemi, Sara
    Zarghi, Afshin
    Sali, Shahnaz
    Zolfaghari, Farnaz
    ARCHIVES OF CLINICAL INFECTIOUS DISEASES, 2020, 15 (05): : 1 - 6
  • [44] The Effect of Nanocurcumin Supplementation on Inflammatory and Biochemical Indicators in Hospitalized Patients With COVID-19: A Randomized Controlled Clinical Trial
    Ahmadi, Sedigheh
    Mohit, Mohsen
    Mehrabi, Zeinab
    Heydari, Mohammad Reza
    Faraji, Seyed Nooreddin
    Yaghoubi, Shoeleh
    Zare, Morteza
    Masoumi, Seyed Jalil
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2024, 2024 (01)
  • [45] Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial
    Niaee, Morteza Shakhsi
    Namdar, Peyman
    Allami, Abbas
    Zolghadr, Leila
    Javadi, Amir
    Karampour, Amin
    Varnaseri, Mehran
    Bijani, Behzad
    Cheraghi, Fatemeh
    Naderi, Yazdan
    Amini, Fatemeh
    Karamyan, Masoumeh
    YadYad, MohammadJafar
    Jamshidian, Ramin
    Gheibi, Nematollah
    ASIAN PACIFIC JOURNAL OF TROPICAL MEDICINE, 2021, 14 (06) : 266 - 273
  • [46] Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial
    Morteza Shakhsi Niaee
    Peyman Namdar
    Abbas Allami
    Leila Zolghadr
    Amir Javadi
    Amin Karampour
    Mehran Varnaseri
    Behzad Bijani
    Fatemeh Cheraghi
    Yazdan Naderi
    Fatemeh Amini
    Masoumeh Karamyan
    Mohammad Jafar YadYad
    Ramin Jamshidian
    Nematollah Gheibi
    Asian Pacific Journal of Tropical Medicine, 2021, 14 (06) : 266 - 273
  • [47] A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia
    Avendano-Sola, Cristina
    Ramos-Martinez, Antonio
    Munez-Rubio, Elena
    Ruiz-Antoran, Belen
    Malo de Molina, Rosa
    Torres, Ferran
    Fernandez-Cruz, Ana
    Calderon-Parra, Jorge
    Payares-Herrera, Concepcion
    Diaz de Santiago, Alberto
    Romera-Martinez, Irene
    Pintos, Ilduara
    Lora-Tamayo, Jaime
    Mancheno-Losa, Mikel
    Paciello, Maria L.
    Martinez-Gonzalez, A. L.
    Vidan-Estevez, Julia
    Nunez-Orantos, Maria J.
    Isabel Saez-Serrano, Maria
    Porras-Leal, Maria L.
    Jarilla-Fernandez, Maria C.
    Villares, Paula
    Perez de Oteyza, Jaime
    Ramos-Garrido, Ascension
    Blanco, Lydia
    Madrigal-Sanchez, Maria E.
    Rubio-Batlles, Martin
    Velasco-Iglesias, Ana
    Pano-Pardo, Jose R.
    Moreno-Chulilla, J. A.
    Muniz-Diaz, Eduardo
    Casas-Flecha, Inmaculada
    Perez-Olmeda, Mayte
    Garcia-Perez, Javier
    Alcami, Jose
    Bueno, Jose L.
    Duarte, Rafael F.
    JOURNAL OF CLINICAL INVESTIGATION, 2021, 131 (20):
  • [48] Efficacy and Safety of Atazanavir/Ritonavir Versus Lopinavir/Ritonavir in Hospitalized COVID-19 Patients: A Randomized Clinical Trial
    Siami, Zeinab
    Dehghan, Danial
    Khavandegar, Armin
    Lak, Mehran
    Bakhtiyari, Mahmood
    IRANIAN RED CRESCENT MEDICAL JOURNAL, 2022, 24 (05)
  • [49] Vitamin D Supplementation and Clinical Outcomes in Severe COVID-19 Patients-Randomized Controlled Trial
    Domazet Bugarin, Josipa
    Dosenovic, Svjetlana
    Ilic, Darko
    Delic, Nikola
    Saric, Ivana
    Ugrina, Ivo
    Stojanovic Stipic, Sanda
    Duplancic, Bozidar
    Saric, Lenko
    NUTRIENTS, 2023, 15 (05)
  • [50] Clinical Trial End Points in Severe COVID-19
    Desai, Aakash
    Kulkarni, Amit
    Rajkumar, S. Vincent
    Gyawali, Bishal
    MAYO CLINIC PROCEEDINGS, 2020, 95 (08) : 1578 - 1580